Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 4/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7094627 | 0.89 | CCR1 (0.47) | CCR1S1PR5HTR2ASIGMAR1MLNR | |
| SCHEMBL18446002 | 0.85 | S1PR5 (0.51) | CCR1S1PR5HTR2ASIGMAR1 | |
| SCHEMBL6994339 | 0.83 | CCR1 (0.48) | CCR1S1PR5MLNRCYP3A4 | |
| SCHEMBL5241550 | 0.81 | CCR1 (0.53) | CCR1S1PR5HTR2ASIGMAR1 | |
| SCHEMBL5242254 | 0.78 | S1PR5 (0.44) | CCR1S1PR5HTR2A | |
| SCHEMBL18418205 | 0.78 | KCNK3 (0.48) | CCR1S1PR5 | |
| SCHEMBL7002631 | 0.77 | MEN1 (0.43) | — | |
| SCHEMBL18422811 | 0.76 | MGLL (0.46) | CCR1S1PR5 | |
| SCHEMBL18418202 | 0.76 | MGLL (0.46) | CCR1S1PR5 | |
| SCHEMBL6993588 | 0.74 | CCR1 (0.48) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326867-A2 | BRIDGED PIPERAZINE DERIVATIVES | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020119961-A1 | Bridged piperazine derivatives | PFIZER INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002032901-A2 | BRIDGED PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119961-A1 | Bridged piperazine derivatives | MYD88, IL4, ARG1 | CCR1 7/4885S1PR5 288/4885HTR2A 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.